News Article | December 2, 2016
According to the latest market report published by Future Market Insights titled, “Bone Growth Stimulators Market: Global Industry Analysis and Opportunity Assessment, 2015-2025”, the bone growth stimulators market is anticipated to expand at a CAGR of 9.5% during the forecast period. Bone growth stimulators are used in cases of delay or failure of fracture healing as they enhance the bone healing process without the sensation of electrical shocks or currents or vibrations when worn by the user. An internal bone growth stimulator or invasive bone growth stimulator is implanted on the fusion site of the bone and it delivers small electrical currents. The internal bone growth stimulator is removed from the body after 6-12 months. External bone growth stimulator or non-invasive bone growth stimulators are externally worn portable devices and do not require surgical implantation. An external bone growth stimulator is prescribed for use for two to nine hours every day for a period of around three to nine months. Economic factors such as improvement in service sector, increase in personal income, and increase in per capita healthcare expenditure are expected to drive market growth globally. Captivating product features, expanding application in the sports medicine industry, high disability cost payments, among others, are fuelling growth of the global bone growth stimulators market. However, various factors such as availability of alternative therapies, uncertainty about efficacy, device-related issues and competition from bone grafts restraint growth of the bone growth stimulators market. By product, the global bone growth stimulators market is segmented into invasive bone growth stimulators, non-invasive bone growth stimulators and ultrasound bone growth stimulators. The non-invasive bone growth stimulators product segment-which comprises capacitive coupling devices, combined magnetic field devices and pulsed ultrasound magnetic field devices-accounts for the highest market share currently and is expected to remain the leading segment in terms of value during the forecast period. In terms of application segmentation, trauma injury and fractures segment is expected to expand at the highest CAGR in terms of value and volume over the forecast period as compared to other applications. Hospitals end user segment, though projected to account for the highest share in market, is expected to expand at an average CAGR in terms of value and volume over the forecast period. Orthopedic clinics and home care end user segments are expected to represent significant market attractiveness indices over the forecast period. By region, North America is expected to remain the market leader in the bone growth stimulators market mainly due to consumer awareness about chronic pain related to bone fracture and injury and subsequent disability costs. Western Europe is the second-largest contributor to the global market in terms of value and volume owing to availability of public health systems and subsidies coupled with reliance of patients on the Internet to research about new technologies, such as bone growth stimulators. MEA is projected to expand at a significant pace mainly due to large (particularly expatriate) population, improvements in life expectancy and decline in mortality rates, combined with increased budgetary spend on healthcare, resulting in a major shift and boost in growth of the bone growth stimulators market in the MEA countries. The MEA bone growth stimulators market is still untapped, so companies have substantial growth opportunities in this region. Key market players covered in this report are DJO LLC, Orthofix International N.V., Zimmer Biomet Holdings Inc., Elizur, Bioventus LLC., Ossatec Benelux BV, Verve Consulting Inc. and IGEA S.p.A. Major players in the bone growth stimulators market are focusing on enhancing their global and regional presence through strategic mergers & acquisitions and operational expansion.
News Article | November 29, 2016
Future Market Insights (FMI) delivers key insights on the Europe viscosupplementation market in its upcoming report titled, “Viscosupplementation Market: Europe Industry Analysis and Opportunity Assessment, 2016-2026”. In terms of revenue, the Europe viscosupplementation market is projected to register a healthy CAGR of 5.1% during 2016-2026. FMI’s report has segmented the market on the basis of product type, end user and region. Based on product type, the market has been segmented into one injection viscosupplementation, three injection viscosupplementation and five injection viscosupplementation. Single injection viscosupplementation product type segment is expected to emerge as the most popular segment over the forecast period, driven by better patient compliance as the treatment reduces the need for multiple hospital visits. The segment is expected to register the highest CAGR of 6.7% during the forecast period. Five injection viscosupplementation product type segment is expected to witness a decline in market share in terms of revenue from 29.0% in 2015 to 23.3% in 2026. This decline is attributed to more incidence of side effects and repeated patient visit requirements associated with five injection viscosupplementation. Reimbursement cutbacks and high injection costs are other factors that can curtail demand for five injection viscosupplementation. By end-users, the market is segmented into hospitals, ambulatory surgical centres and orthopaedic clinics. Hospitals end-use segment is expected to witness significant demand for viscosupplementation, registering a CAGR of 4.3% over the forecast period. Better reimbursement options and increasing patient preference for single injection cycle for osteoarthritis treatment is expected to drive demand for one injection viscosupplementation in the orthopaedic clinics segment over the forecast period. Key trends in the viscosupplementation market are the use of single injection cycle for osteoarthritis treatment and introduction of new combination products in the market. For example, the product pipeline of major players in the viscosupplementation market involves combining corticosteroid injections, which help in relieving pain associated with osteoarthritis, with long-lasting effects of hyaluronic acid, which lasts for nearly six months. Further, regional competition within EU countries, especially in five injection cycle, is leading to entry of new market players. Europe is a mature market in terms of generic products and it is therefore relatively easier to obtain CE mark in Europe than it is to obtain the U.S. FDA approval. Western Europe has been estimated to dominate the Europe viscosupplementation market in 2015, attributed to factors such as the presence of key regional players, strong distribution network and better healthcare infrastructure in the region. Some key players in the Europe viscosupplementation market are Anika Therapeutics Inc., Sanofi S.A., Zimmer Biomet Holdings, Meda AB, Ferring B.V, Fidia Pharmaceutici S.p.A, and Bioventus LLC. We have discussed individual strategies followed by these companies in terms of enhancing product designs, creating new manufacturing facilities, market consolidation and advanced R&D initiatives. The report concludes with key takeaways that could help players already present in the market and new players planning to enter the market in the long run.
News Article | December 7, 2016
There are over 1.8 million total trauma fixation procedures performed in the United States so far this year, as a result, the orthopedic trauma device market is expected to reach over $4 billion by 2023 VANCOUVER, BC--(Marketwired - December 07, 2016) - According to a new series of reports on the U.S. orthopedic trauma device market by iData Research (www.idataresearch.com), one of the major drivers of this market is the consistent influx of newer technologies replacing traditional devices like plates and screws with higher cost of anatomical contouring hybrid locking titanium systems. "The largest segment in the total trauma device market is the plate and screw market," explains Dr. Kamran Zamanian, CEO of iData. "The relatively large size of this segment is due to the popularity of this fixation option manifested in a high volume of unit sold and complimented with relatively strong average selling prices (ASPs)." The majority of total trauma market unit sales consist of devices used in the hospital setting and outpatient facilities, such as ambulatory surgery centers (ASCs). The fastest growing part of this market is the staple fixation segment. This segment is also expected to remain the fastest growing through 2023. The main reasons for the strong growth of this segment is the increasing adoption of nitinol based staples and its popularity due to the reduced operating times it allows when compared to screws. The market is limited by purchasing entities and third-party insurers reducing budgets by ignoring the differences between the various type of plates and screws. In such circumstances, a single price is set for what the entity would be willing to pay for a certain construct, which discourages the use of the more expensive options available on the market. In the case of conventional hip screws, the decline is due to the growing popularity of competing trochanteric hip nail systems. Although trochanteric hip nail systems are continuing to take share of this growing indication, there is a possibility of the conventional hip screw market regaining some popularity as the reimbursement environment becomes more restrictive, giving hospitals fewer options. As a result, their substantially lower ASPs would make them more attractive to cost-conscious purchasers. Although the trauma market is maturing, there are still significant growth niches which could be explored. Recent acquisitions of key products by major trauma companies are expected to unlock significant growth over the next several years. DePuy Synthes leads the U.S. orthopedic trauma market by maintaining its majority share of the plate and screw market, as well holding a top position in most of the other segments. Stryker continues to dominate the intramedullary hip screw market, as well as maintain a key position in several other major segments, securing it the second leading spot in the overall market. Additional competitors in the U.S. orthopedic trauma device market include Zimmer Biomet, Smith & Nephew, Bioventus, Wright Medical, Acumed, Orthofix, Arthrex, DJO Global, I.T.S, Integra LifeSciences, BioPro, ConMed, OsteoMed and Vilex among others. More on the orthopedic trauma device market in the U.S. can be found in a series of reports published by iData Research entitled the US Market Report Suite for Orthopedic Trauma Devices 2017. The suite covers reports on the following markets: plates and screws, bioabsorbable trauma fixation, intramedullary nails, cannulated screws, intramedullary hip nails, conventional hip fixation, bone staples, bone pins, external fixation and bone growth stimulators. The iData report series on orthopedic trauma devices covers the U.S., Brazil, Japan, China, India and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about orthopedic trauma device market data or procedure data, register online or email us at firstname.lastname@example.org for a US Market Report Suite for Orthopedic Trauma Devices 2017 brochure and synopsis. iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.
News Article | March 2, 2017
Research and Markets has announced the addition of the "Global Arthroscopy Market Analysis 2016 - Forecast to 2022" report to their offering. The market assessment is performed through standard and the tailored research methodology approach. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments. Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities. - Market Sizing estimations and forecasts for 6 years across the given market segments - Identifying market dynamics (Drivers, Restraints, Opportunities, Threats, Challenges and Opportunities, ) - Strategic recommendations in key business segments based on the market estimations - Regional and country level market analysis - Competitive landscaping of major market players - Company profiling covering the financials, recent activities and the future strategies 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry 6 Arthroscopy Market, By Application 6.1 Introduction 6.2 Back and Spine Arthroscopy 6.3 Elbow Arthroscopy 6.4 Foot and Ankle Arthroscopy 6.5 Hand and Wrist Arthroscopy 6.6 Hip Arthroscopy 6.7 Knee Arthroscopy 6.8 Shoulder Arthroscopy 6.9 Sports Medicines 9 Vendor Landscaping 9.1 Agreements, Partnerships, Collaborations and Joint Ventures 9.2 Acquisitions & Mergers 9.3 New Product Launch 9.4 Expansions 9.5 Other Key Strategies 10 Company Profiling 10.1 Smith & Nephew plc 10.2 Arthrex Inc. 10.3 Active Implants 10.4 Azellon 10.5 Biomimedica 10.6 BioTek Instruments India Pvt Ltd. 10.7 Bioventus 10.8 Cayenne Medical 10.9 ConMed Corporation 10.10 DePuy Synthes 10.11 DJO Global 10.12 Flexion Therapeutics 10.13 MinInvasive 10.14 NuOrtho Surgical, Inc. 10.15 OrthoSpace 10.16 Stryker Corporation 10.17 Zimmer Biomet For more information about this report visit http://www.researchandmarkets.com/research/klxxjv/global
News Article | February 23, 2017
Cellular allografts currently comprise the fastest growing segment of the orthopedic biomaterials market in the U.S.; the high average selling price of cellular allografts provides incentives for new players to enter the market VANCOUVER, BC--(Marketwired - February 23, 2017) - In a recent article by iData Research Inc. (www.idataresearch.com), a global medical market research firm, on the U.S. market for orthopedic biomaterials, leading competitors are diversifying their product portfolios in order to penetrate higher growth segments. These markets include cellular allografts, cell therapy, synthetic bone graft substitutes and the single-injection hyaluronic acid markets. Competitors in low growth or declining segments are looking outside their traditional space by expanding into other existing segments. For example, Bioventus, the leader in the five-injection hyaluronic acid market, has shifted its focus towards the fast growing single- and triple-injection treatment products. Bioventus is achieving this through securing exclusive U.S. distribution rights for IBSA's three-injection Gelsyn-3™, as well as trying to secure premarket approval for its existing single-injection product, Durolane®, in the United States. In the article, iData Senior Partner and CEO, Kamran Zamanian states: "The synergies between the traditional bone graft substitute materials such as demineralized bone matrix (DBM) and allografts provide a platform for companies that operate within those markets to pursue growth by expanding into the cellular allograft market to complement their product portfolio. As new competitors enter the market, prices should decline, which will aid in greater adoption and, in turn, fuel the number of procedures using cellular allografts." The competitive landscape in the U.S. orthopedic biomaterials market has not significantly changed in terms of rankings, but the strategies of individual companies have. In particular, the leading competitors have aligned with consumer and physician demand to emphasize convenience over price. Treatments that speed up recovery are central to the future of the orthopedic biomaterials market and the high cost of development provides a barrier to entry for new competitors. Nevertheless, continued innovation and development of such products is the key for future growth. More on the orthopedic biomaterials market in the U.S. can be found in a series of reports published by iData entitled the U.S. Market Report Suite for Orthopedic Biomaterials. This report covers the following market segments: orthopedic bone graft substitutes, orthopedic growth factors, cellular allografts, orthopedic cell therapy, orthopedic hyaluronic acid viscosupplementation, orthopedic cartilage repair, and spinal machined bone allografts. The iData series on the market for orthopedic biomaterials covers the U.S., Japan, South Korea, Australia, China, India and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about orthopedic biomaterials device market data or procedure data, register online or email us at email@example.com for an U.S. Market Report Suite for Orthopedic Biomaterials brochure and synopsis. iData Research (www.idataresearch.com) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Orthopedics, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Endoscopy, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Anesthesiology, Wound Management, Ophthalmics, Dental Operatory Equipment and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.
Bioventus | Date: 2016-02-04
Disclosed are various bioactive grafts and methods of making the same. In one embodiment, bone material is harvested from a donor. The harvested bone material is exposed to a lysing agent, the lysing agent configured to release growth factors and bioactive materials from cellular material of the harvested bone material. The harvested bone material is then rinsed with a rinsing agent. The pH of the harvested bone material is substantially neutralized.
News Article | November 7, 2016
DURHAM, Carolina do Norte--(BUSINESS WIRE)--A Bioventus, líder mundial em soluções ortobiológicas, anunciou hoje a nomeação de Andrew McCartney como diretor administrativo internacional para a região da Europa, Oriente Médio e África (Europe, Middle East and Africa, EMEA). McCartney, que será responsável por comandar os negócios da empresa na EMEA e o crescente portfólio de terapias de cura ativa Active Healing Therapies da Bioventus em toda a região, ficará a cargo também do escritório central
News Article | November 16, 2016
HOOFDDORP, Países Bajos--(BUSINESS WIRE)--Bioventus, un líder en soluciones ortobiológicas, ingresó al mercado de la atención de pacientes en México. Este anuncio refleja el crecimiento continuo de la empresa en los mercados internacionales y su misión de asociarse con la comunidad de la atención médica para ayudar a las personas a retomar y disfrutar la vida activa. El producto inicial de Bioventus disponible en México es DUROLANE, una terapia con inyección única de fluido en articulaciones ba
News Article | November 7, 2016
M. McCartney rejoint Bioventus en provenance de Stryker dont il a gravi progressivement les échelons ces dix dernières années en occupant des postes de direction dans les ventes, le marketing et la gestion des unités d'exploitation. Il occupait encore récemment le poste de vice-président directeur général de la Division chirurgicale de Stryker Europe, et avant cela le poste de directeur général de MedSurg Stryker pour le Royaume-Uni et l'Irlande. Il a débuté sa carrière il y a près de 20 ans dans l'industrie des dispositifs médicaux auprès de distributeurs au Royaume-Uni en acquérant de l'expérience dans divers segments tels que le soins des plaies, la surveillance des patients et la cardiologie diagnostique à la fois dans le cadre des services de santé de courte durée et de première ligne. Bioventus LLC est une société orthobiologique qui offre des produits cliniquement éprouvés et rentables qui aident les patients à cicatriser rapidement et sans risque. Sa mission est de faire la différence en aidant les patients à renouer avec leurs activités et à mener une vie active. Bioventus possède deux portefeuilles de produits pour l'orthobiologie, Bioventus Active Healing Therapies et Bioventus Surgical, qui en font un leader mondial dans le domaine de la cicatrisation orthopédique active. S'engageant à respecter des normes de qualité élevées, à pratiquer une médecine fondée sur des données probantes et à adopter un comportement éthique rigoureux, Bioventus est un partenaire de confiance pour les médecins du monde entier.
News Article | November 7, 2016
McCartney war vor Bioventus bei Stryker tätig, wo er in den letzten 10 Jahren seine Laufbahn schrittweise durch Führungsrollen in Vertrieb, Marketing und Positionen im Geschäftseinheits-Management ausgebaut hat. Zuletzt war er als Vice President und General Manager der Surgical Division von Stryker Europe und zuvor als General Manager, MedSurg, Stryker UK & Ireland tätig. Er begann seine fast 20-jährige Karriere in der Medizintechnikbranche mit Distributoren in Großbritannien und sammelte Erfahrungen in mehreren Segmenten einschließlich Wundversorgung, Patientenüberwachung und Diagnose-Kardiologie in primären und akuten Gesundheitseinrichtungen.